Clinical Trial

Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression

Study acronym: FamD_2025
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 12, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Cognitive deficits, including working memory deficits, are often present in depression and there are currently no effective pharmacological treatments targeting working memory deficits. Papassotiropoulos et al. (2024) has recently demonstrated that fampridine, a potassium channel blocker, can enhance working memory in healthy individuals with lower baseline performance, suggesting it may hold potential for addressing cognitive deficits in clinical populations. The primary aim of this study is to evaluate whether fampridine improves working memory performance in mild to moderate depression
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-12-20; most recent amendment 2025-12-04.
Status change: Not Yet Recruiting → Recruiting 2025-06-02
Trial Details
NCT Number NCT06751784
Lead Sponsor University of Basel
Collaborators: Clinical Trial Unit, University Hospital Basel, Switzerland
Conditions Working Memory, Mild to Moderate Depression
Enrollment 38 participants
Start Date 2025-05-22
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-12